autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. we are building a leading biotechnology company focussed on the development and commercialisation of engineered t-cell therapies for haematological and solid tumours. autolus has the ambition to be a leader of a revolution in medicine in which life-threatening diseases are treated by a patient’s own cells.
Company profile
Ticker
AUTL
Exchange
Website
CEO
Christian Martin Itin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Autolus Therapeutics Ltd
SEC CIK
Corporate docs
Subsidiaries
Autolus Holdings (UK) Limited • Autolus Limited • Autolus Inc. • Autolus GmbH • Autolus Switzerland AG ...
AUTL stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
21 Mar 24
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
21 Mar 24
8-K/A
Results of Operations and Financial Condition
15 Mar 24
8-K
Results of Operations and Financial Condition
14 Mar 24
D
Exempt offering of security
23 Feb 24
8-K
Regulation FD Disclosure
13 Feb 24
424B5
Prospectus supplement for primary offering
9 Feb 24
8-K
Autolus Announces Pricing of Underwritten Offering
8 Feb 24
8-K
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
8 Feb 24
S-3ASR
Automatic shelf registration
7 Feb 24
Transcripts
AUTL
Earnings call transcript
2023 Q3
2 Nov 23
AUTL
Earnings call transcript
2023 Q2
3 Aug 23
AUTL
Earnings call transcript
2023 Q1
4 May 23
AUTL
Earnings call transcript
2023 Q1
4 May 23
AUTL
Earnings call transcript
2022 Q4
7 Mar 23
AUTL
Earnings call transcript
2022 Q3
5 Nov 22
AUTL
Earnings call transcript
2022 Q2
8 Aug 22
AUTL
Earnings call transcript
2022 Q1
8 May 22
AUTL
Earnings call transcript
2021 Q4
10 Mar 22
AUTL
Earnings call transcript
2021 Q3
4 Nov 21
Latest ownership filings
SC 13D/A
Kellnerova Renata
25 Mar 24
SC 13D
BioNTech SE
21 Feb 24
SC 13G/A
Paradigm Biocapital Advisors LP
14 Feb 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
Syncona Portfolio Ltd
13 Feb 24
SC 13G/A
Tetragon Financial Management LP
31 Jan 24
SC 13G
Paradigm Biocapital Advisors LP
10 Jul 23
SC 13G
Tetragon Financial Management LP
20 Mar 23
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 23
Financial summary
Quarter (USD) | Sep 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 256.85 mm | 256.85 mm | 256.85 mm | 256.85 mm | 256.85 mm | 256.85 mm |
Cash burn (monthly) | 41.97 mm | 4.49 mm | 16.93 mm | 7.26 mm | (no burn) | 1.09 mm |
Cash used (since last report) | 251.09 mm | 26.83 mm | 101.28 mm | 43.41 mm | n/a | 6.51 mm |
Cash remaining | 5.76 mm | 230.01 mm | 155.57 mm | 213.44 mm | n/a | 250.34 mm |
Runway (months of cash) | 0.1 | 51.3 | 9.2 | 29.4 | n/a | 229.9 |
Institutional ownership, Q3 2023
67.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 75 |
Opened positions | 11 |
Closed positions | 8 |
Increased positions | 14 |
Reduced positions | 24 |
13F shares | Current |
---|---|
Total value | 255.94 bn |
Total shares | 155.95 mm |
Total puts | 0.00 |
Total calls | 142.30 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Syncona Portfolio | 21.35 mm | $49.74 bn |
BX Blackstone | 20.49 mm | $47.73 bn |
Qatar Investment Authority | 15.00 mm | $27.75 mm |
Deep Track Capital | 15.00 mm | $34.95 bn |
PPF Capital Partners Fund B.V. | 14.61 mm | $29.81 mm |
Paradigm Biocapital Advisors | 14.41 mm | $33.57 bn |
Polygon Management | 12.00 mm | $27.96 bn |
Tetragon Financial Management | 9.46 mm | $18.83 mm |
Armistice Capital | 6.90 mm | $16.08 bn |
Frazier Life Sciences Management | 3.75 mm | $8.73 bn |
News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
20 Mar 24
Breaking Down Autolus Therapeutics: 4 Analysts Share Their Views
18 Mar 24
12 Health Care Stocks Moving In Friday's After-Market Session
15 Mar 24
Needham Maintains Buy on Autolus Therapeutics, Maintains $9 Price Target
14 Mar 24
Earnings Scheduled For March 14, 2024
14 Mar 24
Press releases
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
14 Mar 24
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
12 Mar 24
Autolus Announces Pricing of Underwritten Offering
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
8 Feb 24
Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)
22 Jan 24